Torre Diagonal 682 : IV Edición de los Premios Veteco-Asefa Ave

Renovació integral d’un edifici existent conservant solament la seva estructura, per a la seva adequació als requeriments i prestacions propis dels actuals edificis d’oficines.

Nouvelles armes thérapeutiques contre le mélanome de stade IV [New therapeutic weapons in stage IV melanoma].

The treatment of stage IV melanoma has been revolutionized over the last years with the development of immunotherapies that, for the first time, have shown a significant benefit in overall survival, as well as with extremely effective targeted therapies, that also led to improved survival. These results are the fruits of an important translational research effort that allowed a rational approach with a very fast clinical development. The treatment of metastatic melanoma is, therefore, an illustration of the new paradigms of modern molecular research in oncology. In this review, we will present the various agents that have made the proof of their clinical benefit, as well as the scientific discoveries that allowed their development. Some of the remaining questions will be touched upon with the ongoing clinical trials. Inclusion of patients in these studies remains the top priority to improve on the clinical care.

Immunomarquage des collagènes I, III et IV, de la laminine et de la fibronectine dans la capsule cristallinienne humaine [Immunolabelling of collagen types I, III and IV, laminin and fibronectin in the human lens capsule].

PURPOSE: To localize collagen types I, III, and IV, laminin and fibronectin in the anterior human lens capsule. MATERIAL AND METHODS: Twenty-one anterior capsules were sampled by capsulorhexis during extracapsular cataract extraction (mean age 71.5). All capsules were labelled by an immunostaining specific for each antibodies. Immunostaining of four capsules was revealed with immunoperoxydase and seventeen using indirect immunofluorescence. RESULTS: Labelling of collagen types I and III was observed throughout the entire thickness of the capsule for each technique, the strongest labelling was found in the base of the epithelial cells with immunofluorescence. Collagen type IV was observed at the base of the epithelial cells whichever technique was used. Laminin could be detected in the inner layer of the capsule, using immunoperoxydase or immunofluorescence. No specific labelling was found for fibronectin using the two techniques. CONCLUSIONS: Different kinds of collagens have been found in capsules, more particularly the type III. The latter does not appear on other ocular basement membrane. Because of this uneven distribution in the capsule's thickness, each collagen might have a specific function.

Collection complète, par ordre chronologique, des lois, édits, traités de paix, ordonnances, déclarations et règlemens d'intérêt général antérieurs à 1789 restés en vigueur : avec des renvois à la législation nouvelle et à la jurisprudence... et une table raisonnée des matières.... IV. [1768-1778] / par M. Walker,...

[Acte royal. 0420-1789]

CRESCIMENTO E OXIDAÇÃO DE EXPLANTES DE BANANEIRA PRATA (Musa AAB) IN VITRO: IV. CONCENTRAÇÕES DE SAIS, ÁCIDOS ASCÓRBICOS E FREQÜÊNCIA DE SUBCULTIVOS

Avaliaram-se diferentes concentrações de sais do meio MS (Murashige & Skoog, 1962), freqüência de subcultivos e adição de ácido ascórbico ao meio de cultura, objetivando o controle da oxidação de explantes de bananeira-'Prata' (Musa AAB) na fase de estabelecimento. Os tratamentos constituíram-se das diluições dos sais do meio MS (100%, 50% e 33,33%), subcultivos (a cada 7 dias, a cada 14 dias e a cada 28 dias) e ácido ascórbico (0 e 25 mg L-1). O delineamento experimental foi inteiramente casualizado, cujos tratamentos foram arranjados em um fatorial 3 x 2 x 2. Utilizaram-se 15 repetições. As avaliações relativas à massa da matéria fresca, altura e oxidação foram feitas aos 28 dias após a inoculação. Quando o período de subcultivos foi maior (28 dias), o crescimento em massa da matéria fresca foi reduzido em função da redução da concentração de sais do meio MS. Para meios de cultura menos concentrados e freqüência maiores de subcultivos, não houve necessidade da adição do ácido ascórbico para a redução do escurecimento e houve uma tendência de maior crescimento em massa dos explantes.

20/4/20, M. Deschanel arrive à la caserne Henri IV pour décorer les gendarmes des Aubrais : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58965

20/4/20, M. Deschanel à la caserne Henri IV [défilé de gendarmes] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58970

Dictionnaire historique et critique. T. IV, Bosc-Caussin / de Pierre Bayle... ; éd. augm. de notes extraites de Chaufepié, Joly, La Monnoie, Leduchat, L.-J. Leclerc, Prosper Marchand, etc...

Collection : Archives de la linguistique française ; 30

Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.

OBJECTIVE: Thrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer which is the most common clinical presentation of ovarian cancer. METHODS: Platelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for whom there were complete follow-up data on progression and survival. Survival and progression free survival of patients with normal platelet counts (150-350 ×10(9)/L) was compared with that of patients with thrombocytosis (>350×10(9)/L) by χ(2) and logrank tests. RESULTS: The median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 273×10(9)/L; range, 153-350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463×10(9)/L; range, 354-631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a median survival of 43 months (range, 3-100). In the group of patients with thrombocytosis, 24 of the 39 patients had died with a median survival of 23 months (range, 4-79). In the entire group of 91 patients there was a statistically significant difference of the overall survival and progression-free survival between the two groups (logrank test P=0.02 and P=0.007, respectively). CONCLUSION: In this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had prognostic value regarding overall survival and progression-free survival.